Summary
The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Official Title
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
Keywords
Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms, Folate receptor alpha, NSCLC, Ovarian cancer, Cervical cancer, Endometrial cancer, Solid tumor, Lung cancer, Breast cancer, Pancreatic cancer, Colorectal cancer, Anti-drug conjugate, Phase I, Chemotherapy, Non-Small-Cell Lung Carcinoma, Pancreatic Neoplasms, Lung Neoplasms, Breast Neoplasms, Bevacizumab, Carboplatin
